Mechanisms of Diuretic Resistance in Heart Failure, Aim 1

Description

This study will employ a randomized order, double-blind, repeated measures dose ranging design. This design was chosen in order to generate multiple within-subject serial loop diuretic dose response exposures. The overall study schema will include 75 heart failure (HF) patients.

Conditions

Heart Failure

Talk to us

Study Overview

On this page

Study Details

Study overview

This study will employ a randomized order, double-blind, repeated measures dose ranging design. This design was chosen in order to generate multiple within-subject serial loop diuretic dose response exposures. The overall study schema will include 75 heart failure (HF) patients.

Mechanisms of Diuretic Resistance in Heart Failure

Mechanisms of Diuretic Resistance in Heart Failure, Aim 1

Condition
Heart Failure
Intervention / Treatment

-

Contacts and Locations

New Haven

Yale University, New Haven, Connecticut, United States, 06510

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Clinical diagnosis of HF
  • * No plan for titration/change of heart failure medical or device therapies during the study period.
  • * Absence of non-elective hospitalizations in the previous 3 months.
  • * At optimal volume status by symptoms, exam, and dry weight
  • * Age \> 18 years
  • * GFR \<20 ml/min/1.73m2 using the Chronic Kidney Disease- Epidemiology (CKD-EPI)equation or use of renal replacement therapies
  • * Use of any non-loop type diuretic in the last 14 days with the exclusion of low dose aldosterone antagonist (e.g., spironolactone or eplerenone ≤50 mg). Examples of non-loop diuretics include but may not be limited to acetazolamide (oral or IV, not ophthalmic), metolazone, Hydrochlorothiazide (HCTZ), chlorthalidone, chlorothiazide, indapamide, triamterene, amiloride, finerenone, spironolactone dose \> 50mg day, eplerenone \> 50mg/day,
  • * History of flash pulmonary edema requiring hospitalization and treatment with biphasic positive airway pressure or mechanical ventilation or a "brittle" volume sensitive HF phenotype such as an infiltrative or restrictive cardiomyopathy (i.e. amyloid cardiomyopathy, etc).
  • * Hemoglobin \< 8 g/dL
  • * Pregnant or breastfeeding
  • * Inability to give written informed consent or comply with study protocol or follow-up visits
  • * Chronic Urinary retention limiting ability to perform timed urine collection procedures

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Yale University,

Jeffrey Testani, PRINCIPAL_INVESTIGATOR, Yale University

Study Record Dates

2026-11-01